Ticker IRLAB-AListed on Nasdaq Stockholm

IRLAB Therapeutics AB

ISIN SE0012675361Filings at the FI

At a glance

Most recent filing on July 9, 2026 — an open-market purchase by James Gamgort on Jul 8, 2026.

Over the past 12 months: 3 open-market purchases and 0 open-market sales.

We hold 43 visible filings, going back to July 10, 2019.

Filings we could not classify with confidence are set aside for review, so they are in none of these counts.

5 of 43 shown

  • James Gamgort Board member
    $1,470Open-market buy
    TradedJul 8, 2026FiledJul 9, 2026
  • James Gamgort Board member
    $30,000Open-market buy
    TradedJul 7, 2026FiledJul 9, 2026
  • Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body
    140,000 SEKOpen-market buy
    TradedNov 20, 2025FiledNov 20, 2025
  • Joakim Tedroff Closely associated: Other member of the administrative, management or supervisory body
    120,000 SEKOpen-market buy
    TradedNov 12, 2025FiledNov 12, 2025
  • Kristina Torfgård Chief executive officer
    140,850 SEKOpen-market buy
    TradedAug 5, 2024FiledAug 5, 2024

Net short positions of 0.5% or more in IRLAB Therapeutics AB that are open today, as the regulator publishes them. Together they come to 0.79% of the shares. Positions below 0.5% are not published, so the real total can be higher.

1 open position, together 0.79%. The holders and their history are part of the subscription.

Källa: Finansinspektionen, November 16, 2026.